People: Daxor Corp (DXR)

Summary

Name	Age	Since	Current Position
Joseph Feldschuh	75	1974	Chairman of the Board, President
David Frankel		2007	Chief Financial Officer
Stephen Feldschuh		2011	Vice President - Marketing and Development
Mario Biaggi	54	2008	Director
Bernhard Saxe	72	2008	Director
James Lombard	78	1989	Independent Director
Robert Willens	65	2002	Independent Director
Martin Wolpoff	69	1989	Independent Director

» Insider Trading

Biographies

Name	Description
Joseph Feldschuh	Dr. Joseph Feldschuh, M.D., is Chairman of the Board, President of Daxor Corp. He is on the staff of Montefiore Medical Center. From 1966 to 1983, Dr. Feldschuh was Director of the Cardiac Metabolic Laboratory at Metropolitan Hospital. He has been a Clinical Associate Professor in both medicine and pathology at New York Medical College and an Assistant Clinical Professor at Cornell Medical School. He performed the basic research at the College of Physicians and Surgeons (Columbia University) on the measurement and prediction of normal human blood volume. He is the co-inventor of the BVA-100 Blood Volume Analyzer and the inventor of the quantitative injection kit for the BVA-100. Originally trained in Endocrinology, he is Board Certified in Cardiology and Internal Medicine. Dr. Feldschuh is the Chief Scientist for the Company. He has been personally involved in measuring blood volume on more than 4,000 patients during his medical career. In addition to his duties as Chief Scientist of Daxor, Dr. Feldschuh is also responsible for managing the Company’s investment portfolio.
David Frankel	Mr. David Frankel is Chief Financial Officer of Daxor Corp., since January 1, 2007. He was Promoted to Chief Financial Officer on January 1, 2007, joined Daxor Corporation at the end of 2005 as the Corporate Treasurer. Prior to joining the Company, Mr. Frankel was employed as a Controller at Strategic Workforce Solutions in New York. Prior to that, Mr. Frankel was the Controller at Stern Stewart & Co. from 1997 to 2004, where he oversaw accounting for nine overseas offices and directly supervised a staff of six in the firm’s New York Office. Mr. Frankel earned his Bachelors Degree (BBA) in Public Accounting from Hofstra University and is licensed as a CPA in New York State.
Stephen Feldschuh	Mr. Stephen Feldschuh is Vice President - Marketing and Development of Daxor Corp. He earned his undergraduate degree in Business Administration (BS) from Boston University in 1988. He obtained his Master’s degree (MBA) in Finance from Baruch College in 1997. After graduating college, he worked for Bear Stearns & Merrill Lynch as a Commodity Broker & Futures Trader. From 1992 to 1997, he joined Daxor as Operations Manager with various responsibilities including Quality Assurance of the laboratory. From mid 1997 to 1999, Mr. Feldschuh was a financial analyst doing Mergers & Acquisitions in the staffing industry for Headway Corporate Resources. Mr. Feldschuh then worked for Delia’s Inc. as a Financial Controller until 2001 when he rejoined Daxor Corporation as Vice President of Operations. In 2003, Mr. Feldschuh was named Chief Financial Officer and Vice President of Operations. In January, 2007, he was named Chief Operating Officer and relinquished the title of Chief Financial Officer. In October 2011, he was named Vice President of Marketing and Business Development and relinquished the title of Chief Operating Officer.
Mario Biaggi	Mr. Mario Biaggi, Jr., Esq., is Director of Daxor Corp. He is a graduate of Fordham Prep where he was a Maroon Key Honor Society Member as well as Columbia College and Columbia Law School where he was the winner of the Frank Hogan Scholarship named in honor of the legendary Manhattan District Attorney. He graduated Phi Beta Kappa, Cum Laude from Columbia College. Mr. Biaggi was admitted to the bar of the State of New York and later established the law firm of Biaggi & Biaggi. Mr. Biaggi is an accomplished civil trial attorney who has worked for a variety of public and private clients including the State of New York and the United Federation of Teachers. Mr. Biaggi was elected and re-elected as a judicial delegate in Bronx County and is a past member of the Board of Directors of the Abbott House, a childcare agency and residential treatment center.
Bernhard Saxe	Mr. Bernhard Saxe, Esq., is Director of Daxor Corp. He is a retired partner in the intellectual property practice group of Foley & Lardner, LLP, and former Vice President of Patent Affairs and Corporate Secretary of Immunomedics, Inc. He is a registered patent attorney and a member of the American Intellectual Property Law Association, American Bar Association and American Chemical Society. He received his J.D. from George Washington University;Ph.D. from Columbia University; and B.A. from Johns Hopkins University in chemistry. Dr. Saxe was named one of the top 10 patent prosecuting attorneys by IP Law and Business, has authored multiple articles pertaining to patent law and given many seminars and lectures on patent law and strategy.
James Lombard	Mr. James A. Lombard is Independent Director of Daxor Corp. He holds an undergraduate degree in Business Administration (BBA) from Iona College and a Masters Degree (MBA) in Marketing, Banking, and Finance from New York University Graduate School of Business Administration. Mr. Lombard has retired as Director, Administrative Services Division of the City Council of New York and actively participates in civic and community affairs. Prior to joining the City Council, he worked in the banking industry and held various administrative positions with Citicorp and other banks.
Robert Willens	Mr. Robert Willens is Independent Director of Daxor Corp. He started an independent consulting firm for investors in early 2008 called Robert Willens LLC. Prior to that he was a Managing Director in the Capital Markets department at Lehman Brothers, Inc., in New York where he specialized in tax and accounting issues and in this capacity advised most areas of the firm regarding the optimal structures for corporate capital transactions. He has been instrumental in developing certain financial “products” with a view towards insuring that these products will provide clients with the desired tax and accounting results. Prior to joining Lehman Brothers in 1987, Mr. Willens was a tax partner in the New York office of what was then known as Peat Marwick. Mr. Willens is a prolific author and has written Taxation of Corporate Capital Transactions, as well as over 200 articles for various professional journals. Each year for the past 10 years, Mr. Willens has been named to Institutional Investor’s “All-American Research” Team. Mr. Willens has been selected, on four different occasions, as one of the 100 “Most Influential Accountants” in the United States by Accounting Today . Mr. Willens serves as Adjunct Professor (Finance Department) at Columbia University’s Graduate School of Business where he teaches the course entitled “Investment Banking Tax Factors.”
Martin Wolpoff	Mr. Martin S. Wolpoff is Independent Director of Daxor Corp. He holds B.A., M.A. and M.S. degrees from the City University of New York. He has been active in community affairs since the 1970's. He has served on his local community board for three decades. He served as Chair of the Board for three years and had been Chair of the Health, Hospitals and Social Services; Education; and Libraries Committees. He was elected to his community school board three times, serving as a board member for nine years and as it's President for three. Mr. Wolpoff sat as a member of a Community Development Corporation board for almost 10 years and was a former member of a Health Systems Agency Board, as well as having been a member and Vice-Chair of the Community Advisory Board for a New York City hospital. He was the non-medical member of the Institutional Review Board of a local hospital. He also served as a member of the board of a volunteer ambulance corps. Mr. Wolpoff is retired from the New York City public school system, having served from 1965 to 2002 as an educator, supervisor and administrator. He is currently an educational consultant and has served as an adjunct university professor.

Basic Compensation

Name	Fiscal Year Total
Joseph Feldschuh	338,406
David Frankel	135,500
Stephen Feldschuh	202,708
Mario Biaggi	--
Bernhard Saxe	--
James Lombard	--
Robert Willens	--
Martin Wolpoff	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Joseph Feldschuh	0	0
David Frankel	0	0
Stephen Feldschuh	0	0
Mario Biaggi	0	0
Bernhard Saxe	0	0
James Lombard	0	0
Robert Willens	0	0
Martin Wolpoff	0	0

Insider Trading

Name	Shares Traded	Price
WILLENS ROBERT	1,000	$7.26
FELDSCHUH JOSEPH	642	$7.35
FELDSCHUH JOSEPH	1,000	$7.25
FELDSCHUH JOSEPH	1,000	$7.15
FELDSCHUH JOSEPH	358	$7.35
FELDSCHUH JOSEPH	115	$7.45
FELDSCHUH JOSEPH	15	$7.45
FELDSCHUH JOSEPH	200	$7.45
FELDSCHUH JOSEPH	220	$7.45
FELDSCHUH JOSEPH	1,000	$7.45
FELDSCHUH JOSEPH	250	$7.45
FELDSCHUH JOSEPH	194	$7.45
FELDSCHUH JOSEPH	906	$7.60
FELDSCHUH JOSEPH	600	$7.65
FELDSCHUH JOSEPH	1,595	$7.55
FELDSCHUH JOSEPH	405	$7.55
FELDSCHUH JOSEPH	333	$7.60
FELDSCHUH JOSEPH	456	$7.65
WILLENS ROBERT	1,000	$7.70
FELDSCHUH JOSEPH	711	$7.65
FELDSCHUH JOSEPH	35	$7.75
FELDSCHUH JOSEPH	529	$7.75
FELDSCHUH JOSEPH	991	$7.95
FELDSCHUH JOSEPH	9	$7.95
FELDSCHUH JOSEPH	2,000	$8.00

» Full list on Insider Trading

People: Daxor Corp (DXR)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: